leucovorin calcium / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 424 Diseases   809 Trials   809 Trials   14393 News 


«12...159160161162163164165166167168169...235236»
  • ||||||||||  Enrollment open, Trial completion date, Trial primary completion date, MSi-H Biomarker, PD(L)-1 Biomarker:  SU2C ACT3: Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer (clinicaltrials.gov) -  Jan 27, 2020   
    P3,  N=400, Recruiting, 
    Recruiting --> Completed Not yet recruiting --> Recruiting | Trial completion date: Feb 2022 --> Feb 2023 | Trial primary completion date: Feb 2021 --> Feb 2022
  • ||||||||||  leucovorin calcium / Generic mfg., cyclophosphamide intravenous / Generic mfg.
    Retrospective data, Journal:  Role of salvage therapy in chemo resistant or recurrent high-risk gestational trophoblastic neoplasm. (Pubmed Central) -  Jan 25, 2020   
    This regimen reduced the tumor size, lowered the tumor stage, and improved the R0 resection rate and survival rate. Salvage therapy with platinum/etoposide based drug regimens in conjunction with surgery and radiation, was successful in achieving significant cure and survival in HR-GTN patients.
  • ||||||||||  Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca, NN1213 / Novo Nordisk
    Enrollment closed, Combination therapy:  LUD2015-005: Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer (clinicaltrials.gov) -  Jan 18, 2020   
    P1/2,  N=75, Active, not recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Mar 2019 --> Jan 2020 | Trial primary completion date: Feb 2019 --> Jan 2020 Recruiting --> Active, not recruiting
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg., irinotecan / Generic mfg.
    Journal:  Interleukin-8 associated with chemosensitivity and poor chemotherapeutic response to gastric cancer. (Pubmed Central) -  Jan 18, 2020   
    The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed to examine ex vivo chemosensitivity to cisplatin, oxaliplatin, 5-fluorouracil (5-FU) and irinotecan...Upregulation of IL-8 after drug intervention might be useful as predictive biomarker in monitoring drug resistance in GC patients; however, this needs to be confirmed among a larger number of patients and with control groups that are properly age-paired. The established primary gastric culture could serve as a valuable tool for chemotherapy screening, while the repeated usage of platinum drugs may result in drug resistance via upregulation of IL-8 levels.
  • ||||||||||  leucovorin calcium / Generic mfg.
    Journal:  Massively parallel RNA device engineering in mammalian cells with RNA-Seq. (Pubmed Central) -  Jan 15, 2020   
    We identify new ribozyme-based RNA devices that respond to theophylline, hypoxanthine, cyclic-di-GMP, and folinic acid from libraries of ~22,700 sequences in total...The large datasets obtained further provide conserved sequence and structure motifs that may be used for rationally guided design. The RNA-Seq approach offers a generally applicable strategy for developing broad classes of RNA devices, thereby advancing the engineering of genetic devices for mammalian systems.
  • ||||||||||  leucovorin calcium / Generic mfg., fluorouracil / Generic mfg.
    Clinical, Journal:  A qualitative transcriptional signature for predicting pathological response of colorectal cancer to FOLFOX therapy. (Pubmed Central) -  Jan 15, 2020   
    In addition, the signature showed a better predictive performance than two published FOLFOX signatures across different datasets and is more suitable for CRC patients treated with FOLFOX than 5-FU based signatures. In conclusion, the REO-based qualitative transcriptional signature can accurately identify the metastatic CRC patients who may benefit from the FOLFOX regimen.
  • ||||||||||  5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
    Enrollment closed, Phase classification, Enrollment change, Metastases:  Rectal Cancer, Adjuvant Chemotherapy, FOLFOX(5-fluorouracil/Leucovorin/Oxaliplatin), Total Mesorectal Excision (clinicaltrials.gov) -  Jan 14, 2020   
    P2,  N=90, Active, not recruiting, 
    In conclusion, the REO-based qualitative transcriptional signature can accurately identify the metastatic CRC patients who may benefit from the FOLFOX regimen. Recruiting --> Active, not recruiting | Phase classification: P3 --> P2 | N=580 --> 90
  • ||||||||||  leucovorin calcium / Generic mfg.
    Clinical, Journal:  PLPHP deficiency: clinical, genetic, biochemical, and mechanistic insights. (Pubmed Central) -  Jan 8, 2020   
    Suspected clinical diagnoses prior to identification of PLPBP variants included mitochondrial encephalopathy (two patients), folinic acid-responsive epilepsy (one patient) and a movement disorder compatible with AADC deficiency (one patient)...Additional studies in human cells and yeast provide the first empirical evidence that PLPHP is localized in mitochondria and may play a role in mitochondrial metabolism. These models provide new insights into disease mechanisms and can serve as a platform for drug discovery.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly
    Biomarker, Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date, Metastases:  Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) -  Jan 8, 2020   
    P2,  N=47, Active, not recruiting, 
    These models provide new insights into disease mechanisms and can serve as a platform for drug discovery. Recruiting --> Active, not recruiting | N=30 --> 47 | Trial completion date: Dec 2019 --> Dec 2020 | Trial primary completion date: Aug 2019 --> Dec 2020
  • ||||||||||  Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
    Trial initiation date, Metastases:  NAPAN: Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer (clinicaltrials.gov) -  Jan 7, 2020   
    P2,  N=122, Recruiting, 
    Trial completion date: Jul 2023 --> Jul 2024 | Trial primary completion date: Jul 2023 --> Jul 2024 Initiation date: Jul 2019 --> Dec 2019
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Trial completion date, Trial primary completion date, Monotherapy, Metastases:  Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC (clinicaltrials.gov) -  Jan 7, 2020   
    P2,  N=2, Active, not recruiting, 
    Trial completion date: Dec 2020 --> Dec 2021 | Trial primary completion date: Dec 2019 --> Jan 2021 Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2020
  • ||||||||||  Decadron (dexamethasone) / Merck (MSD), Oncaspar liquid (pegaspargase) / Servier
    Trial primary completion date:  DFCI 16-001: Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents (clinicaltrials.gov) -  Jan 6, 2020   
    P3,  N=400, Recruiting, 
    Trial completion date: Oct 2020 --> Oct 2021 | Trial primary completion date: Oct 2019 --> Oct 2020 Trial primary completion date: Dec 2021 --> Dec 2022
  • ||||||||||  leucovorin calcium / Generic mfg., methotrexate / Generic mfg., doxycycline / Generic mfg.
    Journal:  Methotrexate and doxycycline interaction: a rare cause of pancytopenia. (Pubmed Central) -  Jan 4, 2020   
    Herein, we present a unique case of rheumatoid arthritis presented with pancytopenia due to low-dose MTX and doxycycline drug interaction. We also report the successful management of pancytopenia and oral ulcers with combination therapy of leucovorin and granulocyte colony-stimulating factor.